LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Amgen Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

290.17 1.13

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

289.48

Max

290.72

Pagrindiniai rodikliai

By Trading Economics

Pajamos

1.1B

1.7B

Pardavimai

-937M

8.1B

P/E

Sektoriaus vid.

26.32

51.198

Pelnas, tenkantis vienai akcijai

4.9

Dividendų pajamingumas

3.3

Pelno marža

21.23

Darbuotojai

28,000

EBITDA

-1.7B

1.2B

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+12.35% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

3.30%

2.40%

Kitas uždarbis

2025-08-05

Kitas dividendų mokėjimo data

2025-09-05

Kita Ex Dividend data

2025-08-15

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-3B

155B

Ankstesnė atidarymo kaina

289.04

Ankstesnė uždarymo kaina

290.17

Naujienos nuotaikos

By Acuity

39%

61%

126 / 380 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Amgen Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-05-01 20:17; UTC

Uždarbis

Amgen 1Q Revenue Up 9% as Many Products Deliver Double-Digit Sales Growth

2025-05-28 18:09; UTC

Uždarbis

Heart Disease Could Be a Goner When These New -2-

2025-05-28 18:09; UTC

Uždarbis

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

2025-05-19 16:13; UTC

Įsigijimai, susijungimai, perėmimai

Regeneron Is Buying 23andMe. The Deal Is a Head Scratcher. -- Barrons.com

2025-05-01 20:01; UTC

Uždarbis

Amgen: FY25 Share Repurchases Not to Exceed $500M

2025-05-01 20:01; UTC

Uždarbis

Amgen: Guidance Includes Estimated Impact of Implemented Tariffs>AMGN

2025-05-01 20:01; UTC

Uždarbis

Amgen Sees FY25 Capital Expenditures About $2.3B

2025-05-01 20:01; UTC

Uždarbis

Amgen: Guidance Doesn't Account for Any Tariffs That Could Be Implemented in Future, Including Sector-specific Tariffs

2025-05-01 20:01; UTC

Uždarbis

Amgen 1Q Repatha Sales $656M >AMGN

2025-05-01 20:01; UTC

Uždarbis

Amgen 1Q EVENITY Sales $442M >AMGN

2025-05-01 20:01; UTC

Uždarbis

Amgen 1Q Worldwide Neulasta Sales $129M >AMGN

2025-05-01 20:01; UTC

Uždarbis

Amgen Sees FY25 Adj EPS $20-Adj EPS $21.20 >AMGN

2025-05-01 20:01; UTC

Uždarbis

Amgen 1Q Net $1.73B >AMGN

2025-05-01 20:01; UTC

Uždarbis

Amgen Sees FY25 EPS $12.21-EPS $13.46 >AMGN

2025-05-01 20:01; UTC

Uždarbis

Amgen 1Q Adj EPS $4.90 >AMGN

2025-05-01 20:01; UTC

Uždarbis

Amgen Sees FY25 Rev $34.3B-$35.7B >AMGN

2025-05-01 20:01; UTC

Uždarbis

Amgen 1Q Worldwide XGEVA Sales $566M >AMGN

2025-05-01 20:01; UTC

Uždarbis

Amgen 1Q Worldwide Prolia Sales $1.1B >AMGN

2025-05-01 20:01; UTC

Uždarbis

Amgen 1Q EPS $3.20 >AMGN

2025-05-01 20:01; UTC

Uždarbis

Amgen 1Q Worldwide Enbrel Sales $510M >AMGN

2025-05-01 20:01; UTC

Uždarbis

Amgen 1Q Rev $8.15B >AMGN

2025-05-01 20:01; UTC

Uždarbis

Amgen 1Q Worldwide Enbrel Sales $510M >AMGN

2025-05-01 20:01; UTC

Uždarbis

Amgen 1Q Rev $8.1B >AMGN

2025-05-01 20:01; UTC

Uždarbis

Amgen 1Q Net $1.73B >AMGN

2025-05-01 20:01; UTC

Uždarbis

Amgen 1Q Worldwide Neulasta Sales $129M >AMGN

2025-05-01 20:01; UTC

Uždarbis

Amgen Sees FY EPS $12.21-EPS $13.46 >AMGN

2025-05-01 20:01; UTC

Uždarbis

Amgen 1Q Worldwide Prolia Sales $1.1B >AMGN

2025-05-01 20:01; UTC

Uždarbis

Amgen 1Q Worldwide XGEVA Sales $566M >AMGN

2025-05-01 20:01; UTC

Uždarbis

Amgen 1Q EPS $3.20 >AMGN

2025-05-01 20:01; UTC

Uždarbis

Amgen Sees FY Adj EPS $20.00-Adj EPS $21.20 >AMGN

Akcijų palyginimas

Kainos pokytis

Amgen Inc Prognozė

Kainos tikslas

By TipRanks

12.35% į viršų

12 mėnesių prognozė

Vidutinis 326.18 USD  12.35%

Aukščiausias 400 USD

Žemiausias 252 USD

Remiantis 22 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Amgen Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

22 ratings

11

Pirkti

10

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

270.44 / 276.44Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

126 / 380 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.